Devyser Diagnostics AB (publ) provides diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation, thalassemia, breast and ovarian cancer, non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company was incorporated in 2004 and is based in Hägersten, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $10.61 | N/A |
Market Cap | $172.76M | N/A |
Shares Outstanding | 16.28M | N/A |
Employees | 111.00 | N/A |